Rehab Centers: Anterior Cruciate Ligament Prevention Strategies: Are They Effective in Young Athletes – Current Concepts and Review of Literature.

Anterior cruciate ligament prevention strategies: are they effective in young athletes – current concepts and review of literature.

Filed under: Rehab Centers

Curr Opin Pediatr. 2012 Dec 27;
Ladenhauf HN, Graziano J, Marx RG

PURPOSE OF REVIEW: Participation in sports is on the rise, with young athletes training year round and specializing at earlier ages, predisposing them to sports-related injuries. Once thought to be rare, injuries of the anterior cruciate ligament (ACL) are being seen with a greater frequency in the paediatric population. Numerous preventive training programmes have been developed. The purpose of this review is to discuss risk factors and the effectiveness of preventive programmes in the young athlete. RECENT FINDINGS: Most ACL prevention programmes take a multifaceted approach, targeting dynamic neuromuscular and proprioceptive deficits. Focus often lies on noncontact mechanisms of injury, jump and landing techniques, and improving movement patterns during pivoting, cutting and change in direction. However, the effectiveness of these programmes in skeletally immature athletes needs to be evaluated. SUMMARY: Early specialization and increased demand for peak performance at a time of major physiological change, lack of physical fitness and neuromuscular deficits have contributed to an increase in ACL injuries in young athletes. Various preventive training programmes have been developed, but their effectiveness is debatable. We encourage young athletes to partake in preseason training programmes focused on strengthening, neuromuscular and proprioceptive training units under the appropriate supervision of qualified personnel.
HubMed – rehab

Long-acting muscarinic receptor antagonists for the treatment of respiratory disease.

Filed under: Rehab Centers

Pulm Pharmacol Ther. 2012 Dec 27;
Cazzola M, Page C, Matera MG

The use of muscarinic receptor antagonists in the treatment of chronic obstructive pulmonary disease (COPD) is well established. More recently, the potential for long-acting muscarinic receptor antagonists (LAMAs) in the treatment of asthma has also been investigated. While LAMAs offer advantages over short-acting muscarinic receptor antagonists, in terms of a reduced dosing frequency, there remains a need for therapies that improve symptom control throughout both the day and night, provide better management of exacerbations and deliver improved health-related quality of life. Furthermore, the potential for unwanted anticholinergic side effects, particularly cardiovascular effects, remains a concern for this class of compounds. Novel LAMAs in clinical development for the treatment of respiratory disease include: aclidinium bromide, NVA237 (glycopyrronium bromide), GP-MDI, EP-101, CHF-5259, umeclidinium bromide, CHF-5407, TD-4208, AZD8683 and V-0162. These compounds offer potential advantages in terms of onset of action, symptom control and safety. In addition, a number of LAMAs are also being developed as combination treatments with long-acting ?(2)-agonists (LABAs) or inhaled glucocorticosteroids, potentially important treatment options for patients who require combination therapy to achieve an optimal therapeutic response as their disease progresses. More recently, compounds such as GSK961081 and THRX-198321 have been identified that combine LAMA and LABA activity in the same molecule, and have the potential to offer the benefits of combination therapy in a single compound. Here, we review novel LAMAs and dual action compounds in clinical development, with a particular focus on how they may address the current unmet clinical needs in the treatment of respiratory disease, particularly COPD.
HubMed – rehab

Construct Validityand Test-retest Reliability of the Fatigue Severity Scale in People with Chronic Neck Pain.

Filed under: Rehab Centers

Arch Phys Med Rehabil. 2012 Dec 26;
Takasaki H, Treleaven J

OBJECTIVE: To investigate appropriate scoring system and uni-dimensionality using Rasch analysis, discriminant validity, and reliability of the Fatigue Severity Scale (FSS) in people with chronic neck pain. DESIGN: Cross-sectional SETTING: Tertiary institution PARTICIPANTS: One-hundred patients with chronic neck pain and 40 asymptomatic controls INTERVENTIONS: Not applicable MAIN OUTCOME MEASURES: The FSS RESULTS: Twenty-six of the 100 participants with chronic neck pain agreed to complete the FSS again within one week after the first administration for the assessment of the test-retest reliability. Two items obviously threatening uni-dimensionality were eliminated and the 7-item FSS was developed through Rasch analyses. The 7-item FSS demonstrated the appropriateness of its 7-point scale and adequate internal consistency (Rasch-generated reliability=.83-.91). The 7-item FSS had negligible floor effect (1%) and ceiling effect (2%). The item-person map demonstrated limited distribution of item difficulty in comparison to the distribution of person ability. The chronic neck pain group demonstrated significantly (P<.001) higher scores in the 7-item FSS than the control group, indicating discriminant validity.The 7-item FSS also demonstrated adequate test-retest reliability with the mean interval of 4.1 days (n=26) for each item (quadratic weighted ?=.83-.94) and as a whole (intra-class correlation coefficients=.95). A 0-100 scale table reflecting Rasch scores was developed and the minimum detectable change was 9.5 in the 0-100 scale. CONCLUSION: The 7-item FSS appears uni-dimensional and reliable, which can be used quickly in clinical practice to gain a basic understanding of fatigue symptoms in people with chronic neck pain. Further, it is possible to modify the 7-item FSS to enhance discriminant ability within people with chronic neck pain by adding additional items enlarging distribution of item difficulty. HubMed – rehab

Reversible lateral trunk flexion treated with a rehabilitation program in a patient with Parkinson’s disease.

Filed under: Rehab Centers

Parkinsonism Relat Disord. 2012 Dec 26;
Kataoka H, Ikeda M, Horikawa H, Ueno S

HubMed – rehab

Find More Rehab Centers Information…